Modulatory effects of vitamin E, acetyl-l-carnitine and α-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model

Experimental and Toxicologic Pathology

Volumn 64, Issue 6, 2012, Pages 549-556

  Ahmed, Hanaa H ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Alzheimer's disease; Dietary supplements; Homocysteine; Inflammatory cytokines; Insulin; Insulin like growth factor

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA TOCOPHEROL; CYANOCOBALAMIN; DONEPEZIL; FOLIC ACID; HOMOCYSTEINE; INSULIN; INTERLEUKIN 1BETA; LEVACECARNINE; SOMATOMEDIN C; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN BLOOD LEVEL; RAT;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BRAIN; CARNITINE; CHOLINESTERASE INHIBITORS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOMOCYSTEINE; INDANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-1BETA; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; THIOCTIC ACID; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN E;

RATTUS;

EID: 84864500549     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2010.11.012     Document Type: Article

References (92)

1. Aguirre N., Barrionuevo M., Ramirez M.J., Del Rio J., Lasheras B. Alpha-lipoic acid prevents 3,4-methyienedioxymethaphetamine (MDMA)-induced neurotoxicity. Neuroreport 1999, 10:3675-3680.
2. Arendt T., Bigl V., Tennstedt A., Arendt A. Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimer's disease. Neurosci Lett 1984, 48:81-85.
3. Arianna V., Laura N., Moroni C., Laura T., Marco B., Simona L., et al. Modification of platelets from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. J Neurobiol Aging 2006, 30:1-8.
4. Bharathi T., Vasudevaraju P., Govindaraju M., Palunisamy A.P., Sambarmurti K., Rao K.S. Molecular toxicity of aluminum in relation to neurodegeneration. Indian J Med Res 2008, 128:545-556.
5. Binienda Z., Virman A., Przybyla-Zawislak B., Schmued L. Neuroprotective effect of l-carnitine in the 3-nitropropionic acid (3-NPA)-evoked neurotoxicity in rats. Neurosci Lett 2004, 367:264-267.
6. Binienda Z., Virmani A. The mitochondriotropic effects of l-carnitine and its esters in the central nervous system. Curr Med Chem Cent Nerv Syst Agents 2003, 3:275-282.
7. Blawen D.H., Poppe W.A., Trischler W. The effect of subacute doses of organophosphorus pesticide, nuvacron, on the biochemical and cytogenetic parameters of mice and their embryos. J Clin Chem Biochem 1983, 21:381-386.
8. Blum W.F., Albertsson-Wikland K., Rosberg S., Rank M.B. Serum levels of insulin-like growth factor-1 (IGF-1) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993, 76:1610-1616.
9. Buchhave P., Zetterberg H., Blennow K., Minthon L., Janciauskiene S., Hansson O., et al. TNF-receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 2008, 31:1877-1884.
10. Busciglio J., Lorenzo A., Yankner R.A. Methodological variables in the assessment of beta-amyloid neurotoxicity. Neurobiol Aging 1992, 13:609-612.
11. Carro E., Torres-Aleman J. The role of insulin and insulin like growth factor.1 in the molecular and cellular mechanism underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004, 490:127-133.
12. Chan A., Tchantchou F., Graves V., Rozen R., Shea T.B. Dietary and genetic compromise in folate availability reduces acetylcholine and cognitive performance: critical role of S-adenosylmethionine. J Health Nutr Aging 2008, 12:252-261.
13. Chandrasekaran K., Giordano T., Brady D.R., Stoll J., Martin L.J., Rapoport S.I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer's disease. Mol Brain Res 1994, 24:336-340.
14. Chavant F., Deguil J., Pain S., Ingrand I., Milin S., Fauconneau B., et al. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2010, 332:505-514.
15. Chen Z.X. Brain cholinesterases: III. Future perspective of AD research and clinical practice. Med Hypotheses 2004, 63:298-307.
16. Cheng X., Yang L., He P., Li R., Shen Y. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non demented patients. J Alzheimer's Dis 2010, 19:621-630.
17. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., et al. Reduced hippocampal-insulin-degrading enzyme in late onset Alzheimer's disease is associated with the apolipoprotein E. epsilon 4 allele. Am J Pathol 2003, 162:313-319.
18. Cunningham C., Campion S., Lunnon K., Murray C.L., Woods J.F., Deaucon R.M., et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neuron degenerative disease. Biol Psychiatry 2009, 65:304-312.
19. Dave K.R., Syal A.R., Katyare S.S. Effect of long-term aluminum feeding on kinetics attributes of tissue cholinesterases. Brain Res Bull 2002, 58:225-233.
20. de la Monte S.M., Wands J.R. Review of insulin and insulin like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimer's Dis 2005, 7:45-61.
21. de La Monte S.M. Insulin resistance and Alzheimer's disease. BMB Rep 2009, 42:475-481.
22. Devaraj S., Jialai I. Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 1999, 19:1125-1133.
23. Dinarello C.A. The interleukin-1 family: 10 years of discovery. Eur Cytokine Netw 1994, 5:517-522.
24. Drury R.A.B., Wallington E.A. Preparation and fixation of tissues in carletons histological technique 1980, Oxford University Press, Oxford, p. 36-56. 4th ed.
25. Dudek H., Datta S.R., Franko T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan O.R., Greenberg M.E. Regulation of neuronal survival by the serine-theronine protein kinase. AKT Sci 1997, 275:661-665.
26. Forlenza O.V., Diniz B.S., Talib L.L., Mendonca V.A., Ojopi E.B., Gattaz W.E., et al. Increased serum IL-1B level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2009, 28:507-512.
27. Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med 2005, 5:77-86.
28. Frantzen F., Faaren A.L., Alfheim I., Adn Nordhei A.K. An enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998, 44:311-316.
29. Frier B.M., Corrall R.J., Pritchard J.L., Sever P.S. Changes in plasma renin activity after hypoglycaemia in sympathectomized man. Clin Sci 1981, 61:245-247.
30. Fusco D., Colloca G., LoMonaco M.R., Cesari M. Effects of antioxidant supplementation on the aging process. Clin Interv Aging 2007, 2:377-387.
31. Garcia T., Esparza J.L., Nogués M.B., Romeu M., Domingo J.L., Gomez M. Oxidative stress status and RNA expression in hippocampus of an animal model of Alzheimer's disease after chronic exposure to aluminum. Hippocampus 2010, 20:218-225.
32. Gasparini I., Xu H. Potential roles of insulin and IGF-1-in AD. Trends Neurosci 2003, 26:404-406.
33. Giunta B., Fernandez F., Nikolic W.V., Obregon Rrapo E., Town T., Tan J. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflamm 2008, 11:5-51.
34. Good P.F., Olanow C.W., Perl D.P. Neuromelanin-containing neurons of the sulstantia nigra accumulate iron and aluminum in parkinson's disease: a LAMMA study. Brain Res 1992, 593:343-346.
35. Gulya K., Rakonczay Z., Kasa P. Cholinotoxic effects of aluminum in rat brain. Neurochemistry 1990, 51:1020-1026.
36. Ho Y.S., Yu M.S., Yang X.F., So K.F., Yuen W.H., Chang R.C. Neuroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine induced toxicity in rat cortical neurons. J Alzheimer's Dis 2010, 19:813-827.
37. Holmquist L., Stuchbury G., Berbaum K., Muscat S., Young S., Hager K., et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007, 113:154-164.
38. Hoyer S., Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral metabolism in early onset dementia of Alzheimer type. J Neural Transm 1989, 75:227-232.
39. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmcol 2004, 490:115-125.
40. Idriss H.T., Naismith J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000, 50:184-195.
41. Inazu M., Matsumiya T. Physiological functions of carnitine and carnitine transporters in the central nervous system. Nihon Shinkei Seishin Yakurigaku Zasshi 2008, 28:113-120.
42. Jacobsen K.T., Adlerz L., Multhaup G., Iverfeldt K. Insulin like growth factor-1 induced processing of amyloid beta precursor protein (APP) and APP like protein 2 is mediated by different metalloproteinases. J Biol Chem 2010, 285:10223-10231.
43. Janowsky D.S., Davish J.M., Oversreet D.H. Antagonism of anticholinesterase (DEP) toxicity by donepezil plus scopolamine: a preliminary study. Pharmacol Biochem Behav 2004, 77:337-343.
44. Jelhub J., Jacques P.F., Wilson P.W., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993, 270:2693-2698.
45. Kamath A.F., Chauhan A.K., Kisucka J., Dole V.S., Loscalzo J., Handy D.E., et al. Elevated levels of Hcy compromise blood brain barrier integrity in mice. Blood 2006, 107:591-593.
46. Kruman I.I., Kumaravel T.S., Lohani A., Pedersen W.A., Cutler R.G., Kruman Y., et al. Folic acid deficiency and Hcy impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of AD. J Neurosci 2002, 22:1752-1762.
47. 12 in plasma and blood samples. Clin Chim Acta 1979, 95:147-149.
48. Lee K.S., Chung J.H., Choi T.K., Suh S.Y., Oh B.H., Hong C.H. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord 2009, 28:281-287.
49. 12, folate and lipids in patients with AD. Dement Geriatr Cogn Disord 2008, 26:384-390.
50. Liu J. The effect and mechanisms of mitochondrial nutrient α-lipoic acid on improving age associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res 2008, 33:194-203.
51. Lowry O.H., Rosebrough N.J., Farr A.L., Randal R.J. Protein measurements with the folin phenol reagent. J Biol 1951, 193:265-275.
52. Lukiw W.J., Percy M.E., Kruck T.P. Nanomolar aluminum induces proinflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem 2005, 99:1895-1898.
53. Mancuso C., Bates T.E., Butter Field D.A., Calafato S., Cornelius C., De-Lorenzo A., et al. Natural antioxidants in Alzheimer's disease. Expert Opin Investig Drugs 2007, 16:1921-1931.
54. McDaid D.G., Kim E.M., Reid R.E., Cleary J., Hare E.O. Parenteral antioxidant treatment preserves temporal discrimination following intrahippocampal aggregated Abeta (1-42) injections. Behav Pharmacol 2005, 16:237-242.
55. Mihalick S.M., Ortiz D., Kumar R., Rogers E., Shea T.B. Folate and vitamin E deficiency impair cognitive performance in mice subjected to oxidative stress: differential impact on normal mice and mice lacking apolipoprotein E. Neuromol Med 2004, 4:197-202.
56. Miller J.W., Green R., Ramos M.I., Allen L.H., Mungas D.M., Jagust W.J., et al. Homocysteine and cognitive function in the Sacramento Area Latino Study on aging. Am J Clin Nutr 2003, 78:441-447.
57. 6 and folate intake in AD and healthy aging. J Nutr Health Aging 2003, 7:160-165.
58. Morris M.C., Evans D.A., Tangney C.C., Bienias J.L., Wilson R.S., Aggarwal N.T., et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 2005, 81:508-514.
59. Morris M.S., Jacques P.F., Rosenberg I.H., Selub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001, 73:927-933.
60. 12 in ameliorating arsenic-induced oxidative damage in pancreatic tissue of rat. J Nutr Biochem 2006, 17:319-327.
61. Nilsson K., Gustafson L., Hultberg B. Relation between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cong Disord 2002, 14:7-12.
62. Nivsarkar M., Banejee A., Padh H. Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep 2008, 60:692-698.
63. Ogasawara Y., Ohata E., Sakamoto T., Ishii K., Takahashi H., Tanabe S. A model of aluminium exposure associated with lipid peroxidation in rat brain. Biol Trace Elem Res 2003, 96:191-201.
64. Park K.M., Bowers W.K. Tumor necrosis factor alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010, 22:977-983.
65. Passos G.F., Figueiredo C.P., Prediger R.D., Silva K.A., Siqueira J.M., Duarte F.S., et al. Involvement of phosphinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairment induced by beta amyloid 1-40 peptide in mice. Brain Behav Immun 2010, 24:493-501.
66. Pavlik N.Y., Doody R.S., Rountree S.D., Darby E.J., Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. Dement Geriatr Cogn Disord 2009, 28:536-540.
67. Remington R., Chan A., Paskavitz J., Shea T.B. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later stage Alzheimer's disease a placebo-controlled pilot study. Am J Alzheimer's Dis Other Dement 2009, 24:27-33.
68. Rimback G., Moehring J., Huebbe P., Lodge J.K. Gene regulatory activity of alpha tocopherol. Molecules 2010, 15:1746-1761.
69. Ritchie K., Lovestone S. The dementias. Lancet 2002, 360:1759-1766.
70. Schliebs R., Heidel K., Apelt J., Gniezdzinska M., Kirazov L., Szutowicz A. Interaction of interleukin-1β with muscarinic acetylcholine receptor mediating signaling cascade in cholinergically differentiated SH-SY5Y cells. Brain Res 2006, 1122:78-85.
71. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 2001, 32:177-180.
72. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002, 346:476-483.
73. Siedlak S.L., Casadesus G., Webber K.M., Pappolla M.A., Atwood C.S., Smith M.A., et al. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic Res 2009, 43:156-164.
74. Silva V.S., Cordeiro J.M., Matos M.J., Oliveira C.R., Goncalves P.P. Aluminum accumulation and membrane fluidity alteration in synaptosomes isolated from rat brain cortex following aluminum ingestion: effect of cholesterol. Neurosci Res 2002, 44:181-193.
75. Streck E.L., Delwing D., Tagliari B., Matte C., Wannmacher C.M., Wajner M., et al. Brain energy metabolism is compromised by the metabolites accumulating in homocystinuria. Neurochem Int 2003, 43:597-602.
76. Suchy J., Chan A., Shea T.B. Dietary supplementation with a combination of α-lipoic acid, acetyl-l-carnitine, glycerophospho-coline docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance. Nutr Res 2009, 29:70-74.
77. Sun X.J., Crimmins D.L., Myers M.J., Miralpeix M., White M.F. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol 1993, 13:7418-7428.
78. Svoboda Z., Kvetina J., Herink J., Bajgar J., Bartosova L., Palicka V., et al. Galantamine antiacetylcholinesterase activity in rat brain influenced by L carnitine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005, 149:335-337.
79. Tarkowski E., Liljeroth A.M., Minthon L., Tarkowski A., Wallin A., Blennow K. Cerebral pattern of pro and anti-inflammatory cytokines in dementias. Brain Res Bull 2003, 61:255-260.
80. Tores-Aleman I. Minireview: mouse models of Alzheimer's dementia current concepts and new trends. Endocrinology 2008, 149:5952-5957.
81. 2+-ATPase activities induced by the in vitro galactosaemia. Pharmacological Research 2004, 49:475-479.
82. Usoro V.O., Mousa S.A. Vitamin E forms in Alzheimer's disease, review of controversial and clinical experiences. Crit Rev Food Sci Nutr 2010, 50:414-419.
83. Van-Exel E., Eikelenboom P., Comijs H., Frolich M., Smit J.H., Stek M.L., et al. Vascular factors and markers of inflammation in offspring with a parental history of late onset Alzheimer disease. Arch Gen Psychiatry 2009, 66:1263-1270.
84. + ATPase. Toxicology 2007, 236:158-177.
85. Walton J.R., Wang M.X. APP expression, distribution and accumulation are altered by aluminum in rodent model for Alzheimer's disease. J Inorg Biochem 2009, 103:1548-1554.
86. Walton J.R. An aluminum based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A a hyperphosphorylated tau, and granulovacuolar degeneration. J Inorg Biochem 2007, 101:1275-1284.
87. Walton J.R. Brain lesions comprised of aluminum-rich cells that lack microtubules may be associated with the cognitive deficit of Alzheimer's disease. Neurotoxicology 2009, 30:1059-1069.
88. Waly M., Olteanu H., Banerjee R., Choi S.W., Mason J.B. Activation of methionine synthase by insulin like growth factor 1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 2004, 9:358-370.
89. + ATPase: the new face of an old player in pathogenesis and apoptotic/hybrid cell death. Biochem Pharmacol 2003, 66:1601-1609.
90. Zhang C.E., Wei W., Liu Y.H., Peng J.H., Tian Q., Liu G.P., et al. Hyperhomocysteinemia increases β amyloid by enhancing expression of γ-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 2009, 174:1481-1491.
91. Zhu X., Raina A.K., Perry G., Smith M.A. Alzheimer's disease: the two hit hypothesis. Lancet Neurol 2004, 3:219-226.
92. Zhu X., Su B., Wang X., Smith M.A., Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 2007, 64:2202-2220.